nach oben

Clinical and Translational Oncology

Erschienen in:

01.06.2020 | Brief Research Article

Stereotactic body radiation therapy for liver metastasis from colorectal cancer: size matters

verfasst von: S. Flamarique, M. Campo, G. Asín, S. Pellejero, A. Viúdez, F. Arias

Erschienen in: Clinical and Translational Oncology | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We analysed our initial experience with SBRT in liver metastasis from colorectal cancer at our institution.

Materials and methods

Between January/2014 and December/2017, 22 patients with 31 LMCCR were treated. Local control (LC) was assessed using the Kaplan–Meier and log-rank tests. We analysed potential prognostic factors for LC: sex, PTV size, number of LM and the radiation scheme.

Results

Median age: 69 years. Prior chemotherapy or local liver treatments: 81.8% and 63.6% of patients, respectively. SBRT consisted of 3 × 20 Gy (42.9%) and 3 × 15 Gy (31.4%). There were 88.5% responses (57.1% CR and 31.4% PR). Median follow-up was 30 months. LC per lesion at 12 and 24 months was 85.3% and 61.8%, respectively. Tumour volumes > 30 cc correlated with worsened 2-year-control rates (90% vs 34.5%) (p = 0.005). There was only a patient with CTC-grade 3 toxicity.

Conclusions

Liver SBRT is a safe and effective treatment that achieves high local control rates. We found a significant correlation between larger LMCRC and worse local control.

Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol. 1986;150(3):195–203.PubMed

Bellier J, De Wolf J, Hebbar M, El Amrani M, Desauw C, Leteurtre E, Truant S. Repeated resections of hepatic and pulmonary metastases from colorectal cancer provide long-term survival. World J Surg. 2018;42:1171–9.PubMed

Quan D, Gallinger S, Nhan C, Auer RA, Biagi JJ, Fletcher GG, et al. The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review. Surgery. 2012;151:860–70.PubMed

Chow FC, Chok KS. Colorectal liver metastases: An update on multidisciplinary approach. World J Hepatol. 2019;11:150–72.PubMedPubMedCentral

Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol. 2009;19:1206–13.PubMed

Cirocchi R, Trastulli S, Boselli C, Montedori A, Cavaliere D, Parisi A, et al. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev. 2012;6:CD006317.

Dawood O, Mahadevan A, Goodman KA. Stereotactic body radiation therapy for liver metastases. Eur J Cancer. 2009;45(17):2947–59.PubMed

Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572–8.PubMed

Habermehl D, Herfarth KK, Bermejo JL, Hof H, Rieken S, Kuhn S, et al. Single-dose radiosurgical treatment for hepatic metastases—therapeutic outcome of 138 treated lesions from a single institution. Radiat Oncol. 2013;8:175.PubMedPubMedCentral

10.

Berber B, Ibarra R, Snyder L, Yao M, Fabien J, Milano MT, et al. Multicentre results of stereotactic body radiotherapy for secondary liver tumours. HPB. 2013;15:851–7.PubMedPubMedCentral

11.

Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Radiat Oncol. 2008;18(4):215–22.

12.

Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. U.S. Department of Health and Human Services. 2017. https://ctep.cancer.gov-docs/CTCAE_v5_Quick_Reference_5x7.

13.

Schwartz LH, Litière S, de Vries E, Bogaerts J, Chen A, Dancey J, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–7.CrossRef

14.

Khajornjiraphan N, Thu NA, Chow PK. Yttrium-90 microspheres: a review of its emerging clinical indications. Liver Cancer. 2015;4(1):6–15. https://doi.org/10.1159/000343876.CrossRefPubMed

15.

Schlick CJR, Merkow RP, Bentrem DJ. Nonresectional regional therapies for metastatic colorectal cancer to the liver. J Surg Oncol. 2019;119:636–41.PubMed

16.

Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011;117:4060–9.PubMed

17.

Scorsetti M, Comito T, Tozzi A, Navarria P, Fogliata A, Clerici E, et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2015;141:543–53.PubMed

18.

Van Der Pool AE, Mendez Romero A, Wunderink W, Heijmen BJ, Levendag PC, Verhoef C, et al. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg. 2010;97:377–82.PubMed

19.

Hoyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellemann H, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45:823–30.PubMed

20.

Joo JH, Park J, Kim JC, Yu CS, Lim SB, Park IJ, et al. Radiación therapy for liver metastases from colorectal cancer. Int J Radiat Oncol Biol Phys. 2017;99(4):876–83.PubMed

21.

Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31:1631–9.PubMed

22.

Feng M, Suresh K, Schipper MJ, Bazzi L, Ben-Josef E, Matuszak MM, et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial. JAMA Oncol. 2018;4:40–7.PubMed

23.

Moon DH, Wang AZ, Tepper JE. A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy. Radiother Oncol. 2018;126:527–33.PubMed

24.

Takeda A, Sanuki N, Tsurugai Y, Iwabuchi S, Matsunaga K, Ebinuma H, et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer. 2016;122:2041–9.PubMed

25.

Lasley FD, Mannina EM, Johnson CS, Perkins SM, Althouse S, Maluccio M, et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1–2 trial of stereotactic body radiation therapy. Pract Radiat Oncol. 2015;5:e443–e44949.PubMed

26.

Méndez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I–II study. Acta Oncol. 2006;45:831–7.PubMed

27.

Stintzing S, Grothe A, Hendrich S, Hoffmann RT, Heinemann V, Rentsch M, et al. Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases. Acta Oncol. 2013;52(5):971–7.PubMed

28.

Jackson WC, Tao Y, Mendiratta-Lala M, Bazzi L, WahlDR SMJ, et al. Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases. Int J Radiat Oncol Biol Phys. 2018;100(4):950–8.PubMed

29.

Petrelli F, Comito T, Barni S, Pancera G, Scorsetti M, Ghidini A. Stereotactic body radiotherapy for colorectal cancer liver metastases: a systematic review. Radiother Oncol. 2018;129(3):427–34.PubMed

30.

Joo JH, Park JH, Kim JC, Yu CS, Lim SB, Park IJ, et al. Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer. Int J Radiat Oncol Biol Phys. 2017;99(4):876–83.PubMed

31.

Méndez Romero A, Keskin-Cambay F, van Os RM, Nuyttens JJ, Heijmen BJM, Ijzermans JNM, et al. Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy. Rep Pract Oncol Radiother. 2017;22(2):126–31.PubMed

32.

Vera R, González-Flores E, Rubio C, Urbano J, Valero Camps M, Ciampi-Dopazo JJ. Multidisciplinary management of liver metastases in patients with colorectal cancer: a consensus of SEOM, AEC, SEOR, SERVEI, and SEMNIM. Clin Transl Oncol. 2020;22:647–62.PubMed

Titel: Stereotactic body radiation therapy for liver metastasis from colorectal cancer: size matters
verfasst von: S. Flamarique
M. Campo
G. Asín
S. Pellejero
A. Viúdez
F. Arias
Publikationsdatum: 01.06.2020
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 12/2020
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-020-02375-x

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Stereotactic body radiation therapy for liver metastasis from colorectal cancer: size matters

Abstract

Purpose

Materials and methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2020

LncRNA DCST1-AS1 downregulates miR-29b through methylation in glioblastoma (GBM) to promote cancer cell proliferation

Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain

FHOD3 promotes carcinogenesis by regulating RhoA/ROCK1/LIMK1 signaling pathway in medulloblastoma

Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer

100% peer review in radiation oncology: is it feasible?

Research progress of tumor microenvironment and tumor-associated macrophages

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie